annual CFF:
$484.30M+$466.48M(+2617.76%)Summary
- As of today (June 17, 2025), DNLI annual cash flow from financing activities is $484.30 million, with the most recent change of +$466.48 million (+2617.76%) on December 31, 2024.
- During the last 3 years, DNLI annual CFF has risen by +$464.96 million (+2403.12%).
- DNLI annual CFF is now -23.70% below its all-time high of $634.75 million, reached on December 31, 2020.
Performance
DNLI Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
-$3.76M+$406.00K(+9.74%)Summary
- As of today (June 17, 2025), DNLI quarterly cash flow from financing activities is -$3.76 million, with the most recent change of +$406.00 thousand (+9.74%) on March 31, 2025.
- Over the past year, DNLI quarterly CFF has dropped by -$504.04 million (-100.75%).
- DNLI quarterly CFF is now -100.75% below its all-time high of $500.27 million, reached on March 31, 2024.
Performance
DNLI quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$19.73M-$504.04M(-104.07%)Summary
- As of today (June 17, 2025), DNLI TTM cash flow from financing activities is -$19.73 million, with the most recent change of -$504.04 million (-104.07%) on March 31, 2025.
- Over the past year, DNLI TTM CFF has dropped by -$536.22 million (-103.82%).
- DNLI TTM CFF is now -103.11% below its all-time high of $634.75 million, reached on December 31, 2020.
Performance
DNLI TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
DNLI Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2617.8% | -100.8% | -103.8% |
| 3 y3 years | +2403.1% | -357.1% | -216.2% |
| 5 y5 years | +7724.0% | -101.9% | -109.8% |
DNLI Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +2617.8% | -100.8% | +79.7% | -103.8% | at low |
| 5 y | 5-year | -23.7% | +7724.0% | -100.8% | +79.7% | -103.1% | at low |
| alltime | all time | -23.7% | +7724.0% | -100.8% | +79.7% | -103.1% | at low |
DNLI Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$3.76M(-9.7%) | -$19.73M(-104.1%) |
| Dec 2024 | $484.30M(+2617.8%) | -$4.17M(-77.5%) | $484.30M(-1.8%) |
| Sep 2024 | - | -$18.56M(-374.7%) | $493.18M(-4.1%) |
| Jun 2024 | - | $6.76M(-98.6%) | $514.23M(-0.4%) |
| Mar 2024 | - | $500.27M(>+9900.0%) | $516.49M(+2798.4%) |
| Dec 2023 | $17.82M(-94.3%) | $4.71M(+88.8%) | $17.82M(-94.3%) |
| Sep 2023 | - | $2.49M(-72.4%) | $312.77M(-0.8%) |
| Jun 2023 | - | $9.02M(+462.3%) | $315.43M(+1.5%) |
| Mar 2023 | - | $1.60M(-99.5%) | $310.81M(+0.0%) |
| Dec 2022 | $310.67M(+1505.7%) | $299.65M(+5714.0%) | $310.67M(+1819.3%) |
| Sep 2022 | - | $5.15M(+17.1%) | $16.19M(+12.8%) |
| Jun 2022 | - | $4.40M(+200.9%) | $14.35M(-15.5%) |
| Mar 2022 | - | $1.46M(-71.7%) | $16.99M(-12.2%) |
| Dec 2021 | $19.35M(-97.0%) | $5.17M(+55.9%) | $19.35M(-18.4%) |
| Sep 2021 | - | $3.31M(-52.9%) | $23.70M(-94.7%) |
| Jun 2021 | - | $7.04M(+84.3%) | $446.29M(+0.8%) |
| Mar 2021 | - | $3.82M(-59.9%) | $442.66M(-30.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $634.75M(>+9900.0%) | $9.52M(-97.8%) | $634.75M(+1.2%) |
| Sep 2020 | - | $425.90M(>+9900.0%) | $627.26M(+210.5%) |
| Jun 2020 | - | $3.42M(-98.3%) | $202.04M(+0.4%) |
| Mar 2020 | - | $195.91M(+9531.9%) | $201.19M(+3150.3%) |
| Dec 2019 | $6.19M(-93.6%) | $2.03M(+199.6%) | $6.19M(+5.9%) |
| Sep 2019 | - | $679.00K(-73.6%) | $5.85M(+0.4%) |
| Jun 2019 | - | $2.57M(+182.9%) | $5.83M(+24.3%) |
| Mar 2019 | - | $908.00K(-46.3%) | $4.69M(-95.2%) |
| Dec 2018 | $97.02M(-67.3%) | $1.69M(+156.8%) | $97.02M(-75.2%) |
| Sep 2018 | - | $658.00K(-54.1%) | $390.92M(+0.1%) |
| Jun 2018 | - | $1.43M(-98.5%) | $390.62M(+0.4%) |
| Mar 2018 | - | $93.24M(-68.5%) | $389.24M(+31.4%) |
| Dec 2017 | $296.32M(-1.4%) | $295.59M(>+9900.0%) | $296.32M(>+9900.0%) |
| Sep 2017 | - | $357.00K(+600.0%) | $732.00K(+95.2%) |
| Jun 2017 | - | $51.00K(-84.3%) | $375.00K(+15.7%) |
| Mar 2017 | - | $324.00K | $324.00K |
| Dec 2016 | $300.48M(+515.0%) | - | - |
| Dec 2015 | $48.85M | - | - |
FAQ
- What is Denali Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Denali Therapeutics?
- What is Denali Therapeutics annual CFF year-on-year change?
- What is Denali Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Denali Therapeutics?
- What is Denali Therapeutics quarterly CFF year-on-year change?
- What is Denali Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Denali Therapeutics?
- What is Denali Therapeutics TTM CFF year-on-year change?
What is Denali Therapeutics annual cash flow from financing activities?
The current annual CFF of DNLI is $484.30M
What is the all time high annual CFF for Denali Therapeutics?
Denali Therapeutics all-time high annual cash flow from financing activities is $634.75M
What is Denali Therapeutics annual CFF year-on-year change?
Over the past year, DNLI annual cash flow from financing activities has changed by +$466.48M (+2617.76%)
What is Denali Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of DNLI is -$3.76M
What is the all time high quarterly CFF for Denali Therapeutics?
Denali Therapeutics all-time high quarterly cash flow from financing activities is $500.27M
What is Denali Therapeutics quarterly CFF year-on-year change?
Over the past year, DNLI quarterly cash flow from financing activities has changed by -$504.04M (-100.75%)
What is Denali Therapeutics TTM cash flow from financing activities?
The current TTM CFF of DNLI is -$19.73M
What is the all time high TTM CFF for Denali Therapeutics?
Denali Therapeutics all-time high TTM cash flow from financing activities is $634.75M
What is Denali Therapeutics TTM CFF year-on-year change?
Over the past year, DNLI TTM cash flow from financing activities has changed by -$536.22M (-103.82%)